Alkermes Hit With Antitrust Suit Over Opioid Use Treatment

Alkermes Plc was sued by a wholesale drug distributor alleging the biopharmaceutical company conspired to delay the generic version of its Vivitrol medication used to treat opioid and alcohol use disorder.

Alkermes induced Teva Pharmaceutical Industries Ltd. to delay until 2027 Teva’s generic version of Vivitrol, an injection treatment used to treat alcohol dependence and to prevent relapse into opioid dependence, according to a proposed class action filed Thursday by Value Drug Co. in the US District Court for the District of Massachusetts.

The Food and Drug Administration approved Vivitrol for alcohol use in 2006 and for opioid use in ...